DexCom, Inc. (DXCM) P/E Ratio History
Deep ValueTrading at 35.2x · 10th percentile of 5-year range · Significant discount to historical valuation · Data 2018–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, DexCom, Inc. (DXCM) trades at a price-to-earnings ratio of 35.2x, with a stock price of $73.57 and trailing twelve-month earnings per share of $2.36.
The current P/E is 68% below its 5-year average of 111.3x. Over the past five years, DXCM's P/E has ranged from a low of 26.8x to a high of 274.0x, placing the current valuation at the 10th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, DXCM trades at a 51% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
The PEG ratio of 3.36 (P/E divided by 47% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, DXCM commands a significant premium over the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our DXCM DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
DXCM Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
DXCM P/E vs Peers
Diabetes care and insulin delivery peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $167B | 25.8 | 3.11 | -51% | |
| $11B | 46.4 | 0.45Best | -40% | |
| $2B | 6.7Lowest | 0.65 | +817%Best | |
| $108B | 22.5 | 3.21 | +3% | |
| $27B | 26.6 | - | +224% | |
| $3B | 31.8 | 7.22 | -15% | |
| $57B | 26.8 | 1.62 | -1% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
DXCM Historical P/E Data (2018–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $62.80 | $2.34 | 26.8x | -80% |
| FY2025 Q4 | Dec 31 2025 | $66.37 | $2.10 | 31.6x | -76% |
| FY2025 Q3 | - | $67.29 | $1.80 | 37.4x | -71% |
| FY2025 Q2 | Jun 30 2025 | $87.29 | $1.44 | 60.6x | -54% |
| FY2025 Q1 | Mar 31 2025 | $68.29 | $1.34 | 51.0x | -61% |
| FY2024 Q4 | - | $77.77 | $1.43 | 54.4x | -59% |
| FY2024 Q3 | Sep 30 2024 | $67.04 | $1.67 | 40.1x | -69% |
| FY2024 Q2 | Jun 30 2024 | $113.38 | $1.62 | 70.0x | -47% |
| FY2024 Q1 | Mar 31 2024 | $138.70 | $1.55 | 89.5x | -32% |
| FY2023 Q4 | Dec 31 2023 | $124.09 | $1.31 | 94.7x | -28% |
| FY2023 Q3 | Sep 30 2023 | $93.30 | $0.91 | 102.5x | -22% |
| FY2023 Q2 | Jun 30 2023 | $128.51 | $0.86 | 149.4x | +14% |
| FY2023 Q1 | Mar 31 2023 | $116.18 | $0.70 | 166.0x | +27% |
| FY2022 Q4 | Dec 31 2022 | $113.24 | $0.81 | 139.8x | +7% |
| FY2022 Q3 | Sep 30 2022 | $80.54 | $0.54 | 149.1x | +14% |
| FY2022 Q2 | - | $74.53 | $0.51 | 146.1x | +12% |
| FY2022 Q1 | - | $127.90 | $0.58 | 220.5x | +68% |
| FY2021 Q4 | Dec 31 2021 | $134.24 | $0.49 | 274.0x | +109% |
| FY2021 Q3 | - | $136.71 | $0.77 | 177.5x | +35% |
| FY2021 Q2 | Jun 30 2021 | $106.75 | $0.74 | 144.3x | +10% |
| FY2021 Q1 | Mar 31 2021 | $89.85 | $0.67 | 134.1x | +2% |
| FY2020 Q4 | - | $92.43 | $0.58 | 158.7x | +21% |
| FY2020 Q3 | Sep 30 2020 | $103.06 | $0.60 | 171.1x | +31% |
| FY2020 Q2 | - | $101.35 | $0.55 | 183.4x | +40% |
| FY2020 Q1 | - | $67.32 | $0.40 | 166.8x | +27% |
| FY2019 Q4 | - | $54.69 | $0.28 | 197.7x | +51% |
| FY2018 Q3 | Sep 30 2018 | $35.76 | $0.12 | 301.3x | +130% |
Average P/E for displayed period: 131.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DXCM — Frequently Asked Questions
Quick answers to the most common questions about buying DXCM stock.
What is DXCM's P/E ratio?
DexCom, Inc. (DXCM) trailing twelve-month P/E ratio is 35.2x, based on TTM diluted EPS of $2.36. The 5-year average P/E is 111.3x and the historical range spans 26.8x to 274.0x.
Is DXCM stock overvalued or undervalued?
DXCM trades at 35.2x P/E, below its 5-year average of 111.3x. At the 10th percentile of its historical range (26.8x–274.0x), the stock is priced at a discount to its own history.
Is DXCM stock expensive?
No, DXCM is not expensive on a historical basis. The current P/E of 35.2x is below the 5-year average of 111.3x and sits at the 10th percentile of its valuation range.
What is DXCM's historical P/E range?
Over the past 5 years, DXCM's P/E ratio has ranged from 26.8x to 274.0x, with a median of 102.5x and an average of 111.3x. The current P/E of 35.2x places the stock at the 10th percentile of this range. Full historical data spans 2018–2026.
How does DXCM's P/E compare to the S&P 500?
DXCM trades at 35.2x P/E versus the S&P 500 median of 25.9x. The 36% premium to the market typically reflects higher expected earnings growth or quality.
How does DXCM's valuation compare to Healthcare peers?
DexCom, Inc. P/E of 35.2x compares to the Healthcare sector median of 23.4x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is DXCM's PEG ratio?
DXCM PEG ratio is 3.36, based on a P/E of 35.2x and EPS growth of 47.2%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.
What is DXCM's earnings yield?
DXCM earnings yield is 2.84%, the inverse of its 35.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.